The topical solution is relevant when supportive symptom management is appropriate for acute, localized issues. It may be part of symptomatic management applied across domains where additional symptomatic support is needed.

Synthol may be commonly used to help with symptoms related to physical discomfort such as localized aches, stiffness, and soreness in the muscles and joints, as well as symptoms related to inflammatory or irritative states arising from minor physical trauma like bruises, and surface discomfort like insect bites. The product may be applied during phases when symptoms become more noticeable and may provide supportive relief when symptoms interfere with daily functioning.

The product's application may assist in easing the burden of temporary, localized distress. The product may play a role in managing symptom clusters that may become disruptive, which contributes to improved comfort during symptomatic periods.

“The product contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.”

Quick Fact: Relief for Musculoskeletal Discomfort

Synthol is generally relevant across conditions characterized by acute or episodic changes where localized symptoms create noticeable functional strain.

Regulatory References

1. French National Agency for the Safety of Medicines and Health Products (ANSM)

Who Can and Cannot Use Synthol?

The population eligibility for Synthol topical solution is strictly defined by regulatory documents, reserving use for specific age groups and explicitly listing contraindications based on patient history and physical condition.

Official Eligibility Summary

Category	Regulatory Status
Age Restriction	Reserved for adults and children over 7 years of age. Use is prohibited in children under 7 [ANSM RCP].
Hypersensitivity	Contraindicated in individuals with known hypersensitivity to the active substances (e.g., Levomenthol, Salicylic acid), related substances (e.g., salicylates, NSAIDs, aspirin), or any excipient [ANSM Notice].
Neurological History	Contraindicated in children and elderly subjects with a history of convulsions (febrile or non-febrile) [ANSM RCP]. Conditional use requires medical advice for patients with a history of epilepsy [ANSM Notice].
Pregnancy/Lactation	Lactation: Use is preferable not to use; application to the breasts is prohibited. Pregnancy: Seek advice from a doctor or pharmacist before use [ANSM RCP].

Application Site Restrictions

The medicine must not be applied to the eyes, injured skin (including burns, wounds, eczema, or oozing lesions), or a large surface area of the body [ANSM RCP]. The official label clearly dictates that use is limited to specified population groups who do not have these specific contraindications or conditions.

Interaction Profile: Restrictions and Pharmacodynamic Effects

The official interaction profile for the components of Synthol is defined by potential systemic constraints related to pharmacodynamic reinforcement and altered metabolite clearance. The regulatory focus is primarily on the known interactions of Chloral Hydrate, as documented in government prescribing information.

Category	Official Regulatory Documentation Statement
Medicinal Product Categories with Documented Interactions	Central Nervous System (CNS) depressants, including opioids, benzodiazepines, and tricyclic antidepressants; Nonsteroidal Anti-inflammatory Drugs (NSAIDs) such as salicylates; Alcohol.
Specific Interacting Medicines	Sodium Oxybate is explicitly restricted as a contraindicated combination.
Mechanistic Basis of Interactions	Pharmacodynamic Reinforcement: The official profile is structured around the risk of additive CNS depression when co-administered with other sedating agents. Pharmacokinetic Clearance Alteration: Certain co-administered drugs officially reduce the excretion rate of the primary active metabolite (trichloroethanol).

Interaction Classifications (High-Level)

Category	Official Regulatory Classification/Basis
Interaction Severity Classification	Contraindicated Combination (with specific agents); Major/Severe (with CNS depressants and alcohol); Significant/Moderate (with agents that decrease metabolite excretion).
Regulatory Basis	The profile is derived from the pharmacovigilance data for the systemic risks of Chloral Hydrate, as documented by national regulatory bodies.

Official Interaction Statements

• Co-administration with CNS depressants is documented to result in an additive CNS depressant effect due to pharmacodynamic reinforcement.
• The combination with Sodium Oxybate is classified as a contraindicated combination due to the severe, potentiated risk of CNS depression.
• Co-administration with Alcohol is a formally documented major drug–substance interaction leading to the potentiation of systemic effects.
• Certain agents, including Acetylsalicylic Acid, are documented to decrease the excretion rate of the primary active metabolite, which may increase systemic exposure.

Connection to the overall interaction profile: The regulatory interaction profile is defined by the severe pharmacodynamic constraint concerning additive CNS depression, which dictates restrictions on co-administration with numerous CNS depressants and alcohol. An additional pharmacokinetic constraint is the officially recognized exposure-modifying interaction involving agents that decrease the component's metabolite clearance.

How Synthol Works: Mechanism of Action

The substance's effect is achieved through a physical, non-pharmacological mechanism centered on the body’s reaction to a foreign material, rather than modulating chemical pathways or receptors.

Foreign Body Reaction and Tissue Encapsulation

This domain involves the body's innate immune system recognizing the injected oil as a non-absorbable foreign material. This response triggers localized inflammation and ultimately leads to immune cells and surrounding tissue forming a fibrous capsule (scar tissue) around the oil deposits. This biological process results in the sustained alteration of local tissue architecture within the injected area.

Space-Occupying Mass and Physical Volume Expansion

The primary physiological effect is driven by the physical presence of the non-metabolized oil mixture, which creates a space-occupying mass within the muscle tissue. Since the oil is not absorbed, metabolized, or removed, the mechanical displacement of existing tissue results in the expansion of local tissue volume, which is the physiological consequence of mechanical displacement. The combined effect of encapsulation and mass displacement alters the tissue's structural architecture through the development of fibrous connective tissue.

How to Use Synthol

Synthol is an externally applied topical solution, and its use must strictly follow the labeled instructions for administration onto the skin. Dosing recommendations are based on the frequency of application to the affected area, as the product is intended for localized and temporary use.

---

Administration Scope and Regimen

Instruction	Official Guideline
Route of Administration	Topical (External use only). The solution must never be ingested.
Dosing Frequency	Apply the solution to the affected area 2 to 3 times per day.
Preparation Requirements	The solution is ready-to-use and must be applied undiluted.
Age-Group Rules	Use is authorized for adults and adolescents over 7 years of age.

---

Procedural Conditions and Application Technique

The method of administration is crucial to the product’s intended use. The solution is applied to the skin of the painful area either by local friction or massage or by using an impregnated compress. This application technique is the core of the procedural structure for administering the product.

Use Protocol Constraints

The application must be limited to intact skin and must not be applied to wounds or damaged areas. Furthermore, the official labeling mandates a key constraint regarding the special procedural conditions: the solution must not be used under an occlusive dressing. This defines the standardized protocol for administering the preparation. The entire use protocol is structured around short-term, symptomatic application confined entirely to the external skin surface.

Research evidence / Overview of Studies for Synthol

Evidence for Use in Temporary Relief of Minor Muscle Aches and Stiffness

Synthol is a fixed-component topical solution, and the research related to its market availability for minor muscle aches and stiffness primarily draws upon the pharmacological data available for its individual ingredients—such as Levomenthol and Salicylic Acid—which are studied as counter-irritants. Dedicated, modern clinical trials, such as Randomized Controlled Trials (RCTs) specifically examining the fixed combination for these outcomes related to physical discomfort, are generally not publicly documented in authoritative scientific literature.

The existing evidence base, which often includes findings from similar products, describes research that has explored short-term topical application in general adult populations experiencing temporary and episodic musculoskeletal symptoms. These studies primarily monitored patient-reported outcomes describing perceived discomfort and localized stiffness. Findings related to these ingredients describe patterns observed in the studies related to temporary, localized patient-reported outcomes describing perceived discomfort.

Evidence for Use in Superficial Relief from Minor Physical Trauma Symptoms

Research supporting the application of Synthol for minor surface symptoms, such as bruises or localized irritation, also relies heavily on the pharmacological properties available for its components—Resorcinol and Salicylic Acid—in dermatological science. Studies have explored the use of these individual agents in conditions where symptoms may vary in intensity, such as those associated with minor, localized skin surface events.

This evidence base contributes to the broader evidence landscape regarding how topical agents with antiseptic qualities have been studied for outcomes linked to inflammatory or irritative states. Data generally show patterns related to how symptoms evolved during the observed periods for these acute episodes.

What Is Still Uncertain About Synthol Research

A key gap is the absence of modern, product-specific, high-quality clinical trials that confirm the effectiveness of the entire fixed-dose combination compared directly to a placebo or its individual active ingredients. The evidence quality varies across studies, relying heavily on the established knowledge of its components. Comparative evidence is lacking to show how Synthol's multi-component approach compares to other topical remedies. The available evidence relates primarily to the general adult populations studied, and data for certain groups remain insufficient, meaning specific studies for older adults or children are generally not publicly documented.

Key Studies & References Final text from the French National Agency for the Safety of Medicines and Health Products (ANSM) for Synthol (Chloral Hydrate, Resorcinol, Salicylic Acid, Levomenthol)

Common questions about Synthol (FAQ)

Q: Is Synthol the same thing as a steroid?

Official information describes Synthol as a topical solution classified as a rubefacient and mild antiseptic. Its effect is based on a physical, non-pharmacological localized action, which differs from how steroid medicines work.

Q: What is the difference between Synthol and Drug X?

Official regulatory documents indicate that there is a lack of comparative evidence to directly show how Synthol's multi-component approach performs against other topical remedies. Information is based on the established profile of Synthol itself, rather than studies that compare its outcomes to other specific treatments.

Q: How long does the effect of a Synthol dose typically last?

Official administration guidance gives insight into the intended duration of effect. The product is specified to be applied to the affected area 2 to 3 times per day, which provides guidance on maintaining the intended effect.

Q: Are there different forms of Synthol (e.g., tablet, liquid, injection)?

Synthol is consistently defined in official documents as a topical solution or liniment. It is intended exclusively for external application onto the skin and is not available in oral (tablet) or injectable forms.

Q: Can a patient split or crush a Synthol tablet?

No, this medicine is not available in a tablet form. Official documentation describes Synthol only as a topical solution or liniment intended for application to the skin.

Q: Is it necessary to take Synthol with food?

Synthol is defined as a topical solution for external use only and must never be ingested. Therefore, instructions regarding taking the product with food or drink do not apply.

Q: Does Synthol need to be adjusted for people with kidney disease?

The regulatory interaction profile notes that certain co-administered drugs can officially reduce the excretion rate of the primary active metabolite (trichloroethanol), which is a constraint related to how the body clears the substance. Official eligibility criteria do not list kidney disease as a contraindication.

Q: Can people with known allergies to certain drugs use Synthol?

Official information restricts use (is Contraindicated) only for individuals with known hypersensitivity to the active substances, related substances (such as salicylates or NSAIDs), or any inactive component (excipient) in the product.

Q: What are the guidelines for discontinuing the use of Synthol?

The official safety profile provides a clear guideline for stopping treatment. It states that the occurrence of any adverse effect (such as a skin reaction) requires the discontinuation of treatment.

Q: Does Synthol affect sleep patterns?

While there is no direct official statement on the product's effect on sleep patterns alone, the regulatory interaction profile notes a risk of additive CNS depression when combined with other sedating agents or alcohol. This is related to the documented risk of additive CNS depression when combined with other agents.

Q: Do studies suggest Synthol is more effective for certain patient groups?

Research evidence indicates that the available data primarily relates to the general adult populations studied. Information to determine if it provides different outcomes or benefits for specific patient groups is generally not publicly documented.

Q: How does Synthol's classification (e.g., Schedule X) affect its use?

Synthol is defined in regulatory documents as a Topical Analgesic, Rubefacient, and Antiseptic preparation. This classification indicates it is intended for localized, external application for temporary relief.

Q: What is the evidence level supporting the use of Synthol?

The evidence base relies heavily on the established pharmacological data for the product's individual ingredients, such as Levomenthol and Salicylic Acid. Official documentation notes an absence of modern, product-specific, high-quality clinical trials that confirm the effectiveness of the entire fixed combination.

Q: Is it possible for Synthol to affect mood or mental state?

The official safety profile notes a documented risk of agitation and confusion in older adults (elderly subjects) due to the presence of terpene derivatives in the solution.

Q: Are there specific warnings for Synthol related to driving or operating machinery?

The regulatory profile focuses on the risk of additive CNS depression when Synthol is co-administered with sedating agents (such as alcohol). However, no explicit, standalone warning regarding impairment while driving or operating machinery is provided.

Q: What does official guidance say about using Synthol long-term?

Official safety notes indicate that long-term or frequent use may lead to localized effects such as irritation and skin dryness due to the solution's alcoholic base.

Q: What is the difference between the 'active' and 'inactive' ingredients in Synthol?

The Active Ingredients are defined by the product label as the components with the intended pharmacological activity. The Inactive Ingredients are components used in the solvent base, such as Geranium Oil and Lemon Oil, which contribute stimulating or aromatic effects to the final solution.

Q: Are there any specific populations where Synthol is not well-studied?

Research evidence indicates that data for certain groups remain insufficient. Studies specifically concerning older adults or children are generally not publicly documented in the authoritative sources.

Official Storage and Disposal Requirements

Official regulatory labeling dictates strict conditions for storing and disposing of Synthol topical solution to maintain its stability and ensure public safety.

Storage Constraints

The medicine must be stored at a temperature that does not exceed 25 C. To prevent the degradation of its components, the product must be protected from light and kept in its original outer packaging. The container must be kept tightly closed at all times. The medicine should not be used after the expiry date printed on the label.

Child Safety

As a mandatory requirement, Synthol must be stored out of the sight and reach of children to prevent accidental exposure.

Disposal Rules

To protect the environment, the medicine should not be thrown into wastewater (such as sinks or toilets) or placed in household garbage. Unused or expired product must be taken to a pharmacist for proper destruction through established pharmaceutical waste programs.